HighGravityDataSigned in · PRO
Guidance history, every release
Raised · a change from the previous releaseSame · restated unchanged— · not stated in that releaseEvery value links to its sentence in the filing
| Metric | Oct 22, 2024 FY24 Q3 | Jan 30, 2025 FY24 Q4 | Apr 22, 2025 FY25 Q1 | Jul 22, 2025 FY25 Q2 | Oct 21, 2025 FY25 Q3 | Jan 12, 2026 FY25 Q4 | Apr 21, 2026 FY26 Q1 | Jul 23, 2026 FY26 Q2 |
|---|---|---|---|---|---|---|---|---|
| For FY2027 | ||||||||
| Operating margins | — | — | — | — | — | New“+75 to +150 basis points by the end of 2027” | — | — |
| Project Nova first wave implementation | — | — | — | — | — | — | New“fall of 2027” | — |
| For FY2026 | ||||||||
| Annual revenues for Co-Lab Solutions | — | — | — | — | New“approximately $1 billion” | — | — | — |
| CoLab revenues | — | — | — | — | — | New“~$1B in revenues in 2026 including Corewell Health” | — | — |
| Net revenues increase: | — | — | — | — | — | — | New“6.8%” – “7.8%” | Raised“8.3%” – “9.2%” |
| Net revenues: | — | — | — | — | — | — | New“$11.78 billion” – “$11.90 billion” | Raised“$11.95 billion” – “$12.05 billion” |
| Revenues | — | — | — | — | — | — | — | New“between $11.95 billion and $12.05 billion” |
| Adjusted diluted EPS | — | — | — | — | — | — | — | New“between $11.05 and $11.25” |
| Adjusted diluted EPS: | — | — | — | — | — | — | New“between $10.63 and $10.83” | Raised“$11.05” – “$11.25” |
| Reported diluted EPS | — | — | — | — | — | — | New“between $9.58 and $9.78” | — |
| Adjusted effective tax rate | — | — | — | — | — | — | — | New“expected to be consistent with 2025” |
| Capital expenditures | — | — | — | — | — | — | New“Approximately $550 million” | Reiterated“Approximately $550 million” |
| Cash provided by operations | — | — | — | — | — | — | New“Approximately $1.75 billion” | Raised“Approximately $1.80 billion” |
| For FY2025 | ||||||||
| Advanced diagnostic tests in 5 key clinical areas revenue | — | — | — | — | — | New“~$1 billion” | — | — |
| Net revenues | — | New“$10.70 billion” – “$10.85 billion” | Reiterated“$10.70 billion” – “$10.85 billion” | Raised“$10.80 billion” – “$10.92 billion” | Raised“$10.96 billion” – “$11.00 billion” | — | — | — |
| Revenue CAGR | — | — | — | — | — | New“4% - 5%” | — | — |
| Targeted capital deployment - acquisitions revenue growth driver | — | — | — | — | — | New“Drives 1% - 2% revenue growth” | — | — |
| Total revenues - acquisition contribution | — | — | — | — | — | New“Includes 1% - 2% growth from new acquisitions” | — | — |
| Total revenues CAGR | — | — | — | — | — | New“4% - 5% CAGR” | — | — |
| Adjusted diluted EPS | — | — | — | New“between $9.63 and $9.83” | Raised“expected to be between $9.76 and $9.84” | — | — | — |
| Adjusted diluted EPS | — | New“between $9.55 and $9.80” | Reiterated“between $9.55 and $9.80” | Raised“$9.63” – “$9.83” | Raised“$9.76” – “$9.84” | — | — | — |
| Adjusted EPS growth plus dividend yield CAGR | — | — | — | — | — | New“high single-digit to low double-digit CAGR” | — | — |
| Reported diluted EPS | — | — | — | New“between $8.60 and $8.80” | Lowered“now expected to be between $8.58 and $8.66” | — | — | — |
| Capital expenditures | — | New“Approximately $500 million” | Reiterated“Approximately $500 million” | Reiterated“Approximately $500 million” | Reiterated“Approximately $500 million” | — | — | — |
| Cash provided by operations | — | New“Approximately $1.45 billion” | Raised“Approximately $1.5 billion” | Raised“Approximately $1.55 billion” | Raised“Approximately $1.8 billion” | — | — | — |
| Free cash flow | — | — | — | — | — | New“Free cash flow growth commensurate with earnings growth” | — | — |
| Invigorate productivity and cost savings target | — | — | — | — | — | New“3% annual productivity and cost savings target” | — | — |
| Targeted capital deployment - acquisitions | — | — | — | — | — | New“~$1.5B acquisitions” | — | — |
| Targeted capital deployment - capital expenditures | — | — | — | — | — | New“$1.5B - $1.7B capital expenditures (~4.5% of revenue)” | — | — |
| Targeted capital deployment - dividends | — | — | — | — | — | New“~$1.0B dividends” | — | — |
| Targeted capital deployment - free cash flow | — | — | — | — | — | New“$3.0B - $3.3B free cash flow” | — | — |
| Targeted capital deployment - operating cash flow | — | — | — | — | — | New“$4.5B - $5.0B operating cash flow” | — | — |
| Targeted capital deployment - share repurchases | — | — | — | — | — | New“~$0.7B share repurchases” | — | — |
| For FY2024 | ||||||||
| Net revenues | New“$9.80 billion” – “$9.85 billion” | — | — | — | — | — | — | — |
| Revenues | New“between $9.80 billion and $9.85 billion” | — | — | — | — | — | — | — |
| Adjusted diluted EPS | New“between $8.85 and $8.95” | — | — | — | — | — | — | — |
| Capital expenditures | New“Approximately $420 million” | — | — | — | — | — | — | — |
| Cash provided by operations | New“Approximately $1.3 billion” | — | — | — | — | — | — | — |
| No period stated | ||||||||
| Total revenues | — | — | — | — | — | New“4% - 5% CAGR” | — | — |
| Adjusted EPS CAGR | — | — | — | — | — | New“7% - 9%” | — | — |
| Adjusted EPS* | — | — | — | — | — | New“7% - 9% CAGR” | — | — |
| M&A targeted financial criteria - EPS accretion | — | — | — | — | — | New“Accretive to adj EPS in year 1” | — | — |
| Advanced diagnostic tests in 5 key clinical areas growth | — | — | — | — | — | New“double-digit growth” | — | — |
| High-growth areas channel growth | — | — | — | — | — | New“>20% CAGR” | — | — |
| Hospitals channel growth | — | — | — | — | — | New“5% - 6% CAGR” | — | — |
| M&A targeted financial criteria - ROIC accretion | — | — | — | — | — | New“Accretive to ROIC (at least 10%) by year 3” | — | — |
| Physicians channel growth | — | — | — | — | — | New“4% - 5% CAGR” | — | — |
| Quarterly dividend | — | New“$3.20 per share annually” | — | — | — | — | — | — |
Values in quotation marks are the company’s words. Change labels compare each statement with the same metric and target year in the previous release. HighGravityData does not judge whether guidance was met.